Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Multiple Myeloma Clinical Trials
Multiple Myeloma clinical trials are recruiting across 198 cities. Here are the cities with the most active studies:
Multiple Myeloma Trial Phases
65 research organizations are sponsoring multiple myeloma trials.
About Multiple Myeloma
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
Clinical trials are advancing new treatments for multiple myeloma. Currently, 100 studies are recruiting a combined 326,400 participants across the United States. Research is being conducted by 65 organizations including NYU Langone Health, Dana-Farber Cancer Institute, UMC Utrecht and 62 others.
2026 Multiple Myeloma Research Landscape
As of July 2026, the multiple myeloma clinical trial landscape includes 100 actively recruiting studies across 198 cities in the United States. These studies are collectively seeking 326,400 participants, with an average enrollment target of 3,264 per study.
The research spans multiple phases of development: 31 studies are in PHASE3, 11 studies are in PHASE2, 9 studies are in NA, 8 studies are in PHASE1, 4 studies are in PHASE4. The presence of Phase 3 trials indicates that some multiple myeloma treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 65 different organizations, including NYU Langone Health, Dana-Farber Cancer Institute, UMC Utrecht, Boston Children's Hospital, Boston Medical Center, and 60 others. The large number of sponsors reflects significant research interest and investment in multiple myeloma treatment advancement.
Geographically, multiple myeloma trials are most concentrated in New York, New York (23 trials); Bethesda, Maryland (17 trials); Atlanta, Georgia (17 trials); Los Angeles, California (15 trials); Denver, Colorado (11 trials) and 7 other cities.
Featured Multiple Myeloma Studies
Highlighted recruiting studies for multiple myeloma, selected by enrollment size and research scope.
Implementation of Communication Disability Collection and Accommodations in Primary Care Settings
This multi-methods-multi-site study aims to adapt and evaluate the effects of an implementation support package of strategies to assist primary care clinics in documenting patients' communication disability (CD) and accommodation needs in the electronic health record (EHR) and providing communication accommodations through EHR data extraction, surveys, focus groups, interviews, and clinical practi...
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in ...
Frequently Asked Questions About Multiple Myeloma Clinical Trials
Are there multiple myeloma clinical trials near me?
Yes, there are 100 multiple myeloma clinical trials currently recruiting across 198+ cities in the United States, including New York, New York; Bethesda, Maryland; Atlanta, Georgia. Browse the studies above to find one at a location convenient for you.
How do I join a multiple myeloma clinical trial?
To join a multiple myeloma clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are multiple myeloma clinical trials free?
Yes, participation in multiple myeloma clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of multiple myeloma treatments are being studied?
Current multiple myeloma clinical trials are testing a range of approaches across PHASE3 (31 studies), PHASE2 (11 studies), NA (9 studies), PHASE1 (8 studies), PHASE4 (4 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 65 research organizations.
Is it safe to participate in multiple myeloma clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov